PotlatchDeltic (PCH) Upgraded By DA Davidson from Underperform; Diffusion Pharmaceuticals (DFFN) Shorts Increased By 67.95%

PotlatchDeltic Corporation (NASDAQ:PCH) Logo

In a a note revealed on 7 May, DA Davidson stated it was upgrading PotlatchDeltic (NASDAQ:PCH) stock from a Underperform to a Neutral.

Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) had an increase of 67.95% in short interest. DFFN’s SI was 1.11 million shares in May as released by FINRA. Its up 67.95% from 659,200 shares previously. With 909,000 avg volume, 1 days are for Diffusion Pharmaceuticals Inc (NASDAQ:DFFN)’s short sellers to cover DFFN’s short positions. The SI to Diffusion Pharmaceuticals Inc’s float is 10.12%. The stock increased 1.42% or $0.008 during the last trading session, reaching $0.558. About 96,539 shares traded. Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) has declined 78.47% since May 7, 2017 and is downtrending. It has underperformed by 90.02% the S&P500.

Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, developing small-molecule drugs that help regulate the movement of oxygen into tissue by a novel mechanism of action. The company has market cap of $28.19 million. The Company’s lead product candidate is trans sodium crocetinate, which is in Phase I/II clinical trials for the treatment of glioblastoma multiforme ; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II/III clinical trials for the treatment of metastatic brain cancer. It currently has negative earnings. The firm is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of macular degeneration; and is in pre-clinical development in oncology applications primarily GBM.

Another recent and important Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) news was published by Prnewswire.com which published an article titled: “Pre-Market Technical Scan on Biotech Equities — Diffusion Pharma, Dynavax Technologies, Edge Therapeutics, and …” on May 01, 2018.

Investors sentiment increased to 1.54 in Q4 2017. Its up 0.24, from 1.3 in 2017Q3. It improved, as 16 investors sold PotlatchDeltic Corporation shares while 62 reduced holdings. 43 funds opened positions while 77 raised stakes. 35.45 million shares or 5.66% more from 33.55 million shares in 2017Q3 were reported. Dekabank Deutsche Girozentrale invested in 4,443 shares or 0% of the stock. Citadel Ltd Liability Corporation holds 28,012 shares or 0% of its portfolio. Schafer Cullen Cap Mgmt holds 0.01% of its portfolio in PotlatchDeltic Corporation (NASDAQ:PCH) for 10,550 shares. Boston Advisors Ltd owns 0% invested in PotlatchDeltic Corporation (NASDAQ:PCH) for 4,055 shares. Swiss Retail Bank invested in 0% or 69,100 shares. Riverhead Mgmt Ltd Liability holds 4,718 shares or 0.01% of its portfolio. New York-based Bnp Paribas Arbitrage has invested 0% in PotlatchDeltic Corporation (NASDAQ:PCH). Pictet Asset Ltd holds 0.15% or 1.17 million shares in its portfolio. Meeder Asset Mgmt holds 0.08% or 18,495 shares. Morgan Stanley invested in 233,211 shares. Robeco Institutional Asset Bv invested in 0.02% or 81,710 shares. Hartford Inc reported 27,323 shares stake. Pnc Financial Group reported 191,676 shares or 0.01% of all its holdings. Brown Advisory Incorporated reported 9,814 shares or 0% of all its holdings. Arrowstreet Lp owns 0.02% invested in PotlatchDeltic Corporation (NASDAQ:PCH) for 154,893 shares.

More recent PotlatchDeltic Corporation (NASDAQ:PCH) news were published by: Globenewswire.com which released: “PotlatchDeltic Corporation Reports First Quarter 2018 Results” on May 03, 2018. Also Seekingalpha.com published the news titled: “PotlatchDeltic’s (PCH) CEO Mike Covey on Q1 2018 Results – Earnings Call Transcript” on May 05, 2018. Nasdaq.com‘s news article titled: “Market Trends Toward New Normal in Acacia Research, A10 Networks, Imperva, PotlatchDeltic, Blackhawk Network …” with publication date: April 27, 2018 was also an interesting one.

Among 8 analysts covering Potlatch (NASDAQ:PCH), 1 have Buy rating, 2 Sell and 5 Hold. Therefore 13% are positive. Potlatch has $55.0 highest and $37 lowest target. $48.40’s average target is -0.72% below currents $48.75 stock price. Potlatch had 26 analyst reports since September 7, 2015 according to SRatingsIntel. The rating was downgraded by DA Davidson on Tuesday, April 11 to “Underperform”. As per Monday, September 7, the company rating was upgraded by Zacks. Raymond James upgraded PotlatchDeltic Corporation (NASDAQ:PCH) on Monday, January 8 to “Outperform” rating. RBC Capital Markets maintained PotlatchDeltic Corporation (NASDAQ:PCH) on Monday, September 4 with “Hold” rating. The firm has “Hold” rating given on Wednesday, November 16 by Vertical Research. As per Wednesday, January 31, the company rating was maintained by RBC Capital Markets. On Monday, February 12 the stock rating was maintained by BMO Capital Markets with “Hold”. The firm has “Outperform” rating given on Friday, June 17 by RBC Capital Markets. The firm has “Underperform” rating given on Wednesday, October 25 by Bank of America. The firm has “Hold” rating given on Friday, October 6 by RBC Capital Markets.

PotlatchDeltic Corporation (NASDAQ:PCH) Institutional Positions Chart